Matthew O’Connor on Cyclarity’s Successful Phase 1 Trial (opens in new tab)

Most cardiovascular trials focus on lowering LDL cholesterol or reducing inflammation to slow disease progression. UDP-003 targets the root cause: toxic 7-ketocholesterol (7KC) inside macrophages and soft plaques. It is designed to […]